Retrophin, Inc. (RTRX) - NASDAQ
  • Mon, Jun. 20, 5:01 PM
    • Retrophin (NASDAQ:RTRX) secures the rights to a liquid formulation of ursodeoxycholic acid (UDCA) from privately held Asklepion Pharmaceuticals for the potential treatment of primary biliary cholangitis (PBC).
    • Under the terms of the license agreement, Asklepion will receive an upfront payment of $0.5M and and up to $23.5M in sales-based milestones. It is eligible to receive up to $35.0M in milestones related to additional indications. Retrophin will assume all future program costs and will pay Asklepion tiered royalties on net sales.
    • Retrophin says it will file a New Drug Application (NDA) for the PBC indication in 2017.
    • UDCA, or ursadiol, is a naturally occurring hydrophilic bile acid derived from cholesterol. A liquid formulation would provide an attractive dosing alternative to patients who have difficulty swallowing pills.
    • In late May, the FDA approved Intercept Pharmaceuticals' (NASDAQ:ICPT) Ocaliva (obeticholic acid), in combination with UDCA, for the treatment of PBC. Both are orally administered in tablet form.
    | Mon, Jun. 20, 5:01 PM
  • Sun, Jun. 5, 8:28 AM
    • Prosecutors have filed new charges accusing Martin Shkreli of engaging in more illegal maneuvers at his old drug company Retrophin (NASDAQ:RTRX) by using employees and consultants to conceal control of his stock.
    • The new eight-count indictment, adding a conspiracy charge, sheds more light on the e-mail communications between Shkreli and his former corporate lawyer, Evan Greebel, who is accused of covering up securities fraud.
    • A court hearing on the case is scheduled for tomorrow.
    | Sun, Jun. 5, 8:28 AM | 8 Comments
  • Tue, May 3, 4:05 PM
    • Retrophin (NASDAQ:RTRX): Q1 EPS of $0.14 beats by $0.36.
    • Revenue of $29M (+67.0% Y/Y) misses by $2M.
    • Press Release
    | Tue, May 3, 4:05 PM
  • Mon, May 2, 5:35 PM
  • Fri, Apr. 15, 11:46 AM
    • Celator Pharmaceuticals (CPXX +4.6%) initiated with Buy rating and $24 (63% upside) price target by Needham.
    • Retrophin (RTRX -1.7%) initiated with Outperform rating and $25 (67%upside) price target by BMO Capital.
    • Fate Therapeutics (FATE -3.2%) initiated with Outperform rating and $4 (85% upside) price target by BMO Capital.
    • Tobira Therapeutics (TBRA +4.4%) initiated with Buy rating and $22 price target by H.C. Wainwright.
    • Wright Medical Group (WMGI +2.4%) initiated with Buy rating and $23 (21% upside) price target by Bank of America.
    • Cleveland Research rates UnitedHealth Group (UNH -0.9%) a Buy with a $155 (22% upside) price target; Anthem (ANTM -0.5%) a Buy with a $170 (20% upside) price target and Aetna (AET -0.4%) Neutral with a $120 (10% upside) price target.
    • Glaukos (GKOS +0.3%) initiated with Hold rating by Stifel.
    • Baxter International (BAX -0.3%) upgraded to Overweight from Neutral by Piper Jaffray. Price target raised to $58 (36% upside) from $39.
    • Baird upgrades Exactech (EXAC +0.7%) to Outperform from Neutral and raises the price target to $26 (18% upside) from $21. Stryker (SYK -0.9%) downgraded to Neutral from Outperform and raises the price target to $116 (6% upside) from $111.
    • Tenet Healthcare (THC -2.5%) upgraded to Positive from Neutral by Susquehanna.
    • Clovis Oncology (CLVS -1.5%) downgraded to Neutral from Overweight by JP Morgan. Price target lowered to $15 (7% upside) from $42.
    • AstraZeneca (AZN +0.3%) downgraded to Sell from Neutral by Goldman Sachs. Price target lowered to 3,700p (11% downside risk) from 4,400p.
    • Intercept Pharmaceuticals (ICPT +0.2%) downgraded to Underweight from Equal Weight by Morgan Stanley. Price target lowered to $80 (48% downside risk) from $100.
    | Fri, Apr. 15, 11:46 AM | 2 Comments
  • Thu, Feb. 25, 4:05 PM
    • Retrophin (NASDAQ:RTRX): Q4 EPS of $0.07 beats by $0.29.
    • Revenue of $30.4M (+117.0% Y/Y) beats by $1M.
    • Press Release
    | Thu, Feb. 25, 4:05 PM | 1 Comment
  • Wed, Feb. 24, 5:35 PM
  • Wed, Feb. 24, 11:23 AM
    • The European Commission designates Retrophin's (RTRX -2%) RE-024 an Orphan Drug for the treatment of pantothenate kinase-associated neurodegeneration ((PKAN)), a rare and life-threatening genetic disorder caused by mutations in the PANK2 gene that results in the accumulation of iron in the brain. There are no approved treatments for the condition.
    • The PANK2 gene encodes a crucial protein that phosphorylates (introduces a phosphate group) vitamin B5 (pantothenate) to phosphopantothenate. The disruption of this metabolic pathway leads to decreased levels of Coenzyme A (CoA), which plays a key role in many cellular functions.
    • RE-024 is a small molecule that serves as phosphopantothenate replacement therapy for PKAN, which leads to the restoration of normal CoA levels.
    • Among the benefits of Orphan Drug status in the EU is a 10-year period of market exclusivity for the indication, if approved.
    | Wed, Feb. 24, 11:23 AM
  • Dec. 18, 2015, 11:14 AM
    | Dec. 18, 2015, 11:14 AM
  • Nov. 3, 2015, 4:14 PM
    • Retrophin (NASDAQ:RTRX): Q3 EPS of -$0.04 misses by $0.13.
    • Revenue of $28M (+235.3% Y/Y) beats by $0.8M.
    • Shares -3.9%.
    | Nov. 3, 2015, 4:14 PM
  • Aug. 18, 2015, 1:01 PM
    • Retrophin (RTRX -3.8%) isn't done with founder and former CEO Martin Shkreli, whom it ousted in October for allegedly paying off underwater hedge fund investors with more than 590K shares of company stock and over $2.7M in company cash.
    • Yesterday, the company filed a lawsuit in New York against Mr. Shkreli seeking $65M in damages and a requirement that he disgorge all the compensation he received from Retrophin during his tenure.
    • In an interview, Mr. Shkreli said the company's claims are "preposterous," relying on half-truths and speculation. Not one to be outdone, he is preparing a lawsuit of his own. Stay tuned.
    • Previously: Retrophin investigation confirms shenanigans of former CEO (Feb. 20)
    | Aug. 18, 2015, 1:01 PM | 6 Comments
  • Aug. 4, 2015, 4:09 PM
    • Retrophin (NASDAQ:RTRX): Q2 EPS of $0.40
    • Revenue of $24.1M (+319.1% Y/Y)
    | Aug. 4, 2015, 4:09 PM | 1 Comment
  • Jul. 6, 2015, 5:03 PM
    • Retrophin (NASDAQ:RTRX) closes the sale of its Rare Pediatric Disease Priority Review Voucher to Sanofi (NYSE:SNY) for $245M, payable via an upfront fee of $150M plus two additional payments of $47.5M, one in 2016 and the other in 2017.
    • The voucher, which Retrophin acquired from Askepion Pharmaceuticals, can be sold or transferred an unlimited number of times. It shortens the FDA's review clock for a New Drug Application (NDA) from 10 months to six, clearly valuable to drug makers.
    • Previously: Retrophin bags $245M from Sanofi for priority review voucher (May 27)
    | Jul. 6, 2015, 5:03 PM
  • Jun. 8, 2015, 11:46 AM
    • In a regulatory filing, Retrophin (RTRX -2.5%) discloses that it settled its lawsuit with Questcor Pharmaceuticals. Under the terms of the settlement, Questcor paid Retrophin $15.5M in exchange for a mutual release of all claims against each other.
    • Retrophin filed the suit on January 7, 2014, accusing Questcor of violating antitrust laws by monopolizing certain therapeutic drug markets. The spat pertained to a synthetic fragment of Acthar Gel called Synacthen that was owned by Novartis. Retrophin offered Novatis $16M for the product with the intent of competing against Acthar. On the day Retrophin was to sign the deal, Questcor offered Novartis $135M, which Novartis accepted, considering that it could keep the money even if Questcor lost its rights to the product on antitrust grounds. Retrophin claimed that Questcor's intent was just to eliminate a competitive threat.
    | Jun. 8, 2015, 11:46 AM | 1 Comment
  • Jun. 5, 2015, 7:54 AM
    • The FDA designates Retrophin's (NASDAQ:RTRX) investigational phosphopantothenate replacement therapy, RE-024, for Fast Track review for the treatment of pantothenate kinase-associated neurodegeneration (PKAN), a rare and lethal autosomal recessive neurodegenerative disorder that affects ~5,000 people worldwide. There are no approved treatments for the disease.
    • PKAN is caused by a mutation in the PANK2 gene, responsible for encoding a protein that metabolizes pantothenate (vitamin B5) to phosphopantothenate. The malfunction leads to decreased levels of Coenzyme A, an important substrate for many cellular processes. This leads to dystonia (sustained muscle contraction that causes abnormal posture), rigidity, dysphagia (difficulty swallowing), weakness, pigmentary retinopathy (vision impairment), tremors and other symptoms.
    • RE-024, currently in Phase 1 development, is a small molecule replacement therapy for phosphopantothenate.
    • Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the New Drug Application (NDA).
    | Jun. 5, 2015, 7:54 AM
  • May 27, 2015, 10:01 AM
    • Retrophin (RTRX +9.4%) jumps out the gate this morning goosed by the news that it has agreed to sell its Rare Pediatric Disease Priority Review Voucher to Sanofi (SNY +2%) for $245M. Under the terms of the sale, Sanofi will pay $150M upon the signing of the contract, $47.5M a year later and another $47.5M two years later.
    • The voucher, which Retrophin acquired from Askepion Pharmaceuticals, can be sold or transferred an unlimited number of times. It shortens the FDA's review clock for a New Drug Application (NDA) from 10 months to six, clearly valuable to drug makers.
    • Previously: Retrophin acquires rights to bile acid disorder drug; shares up 38% premarket (March 18)
    | May 27, 2015, 10:01 AM
Company Description
Retrophin, Inc. operates as a development stage company, which develops pharmaceutical products for the treatment of rare diseases. It currently focuses on the discovery and development of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently... More
Sector: Healthcare
Industry: Biotechnology
Country: United States